Shares of Soleno Therapeutics (NASDAQ: SLNO) tumbled 15.43% in after-hours trading on Tuesday, following the release of the company's third-quarter 2025 financial results. The significant drop came as a surprise to many investors, given the seemingly positive earnings report.

For the quarter ended September 30, 2025, Soleno reported impressive financial results, including: - Revenue of $66.0 million - Net income of $26.0 million, or $0.47 per diluted share - Operating income of $22.1 million The company also highlighted the successful U.S. launch of VYKAT XR, its treatment for hyperphagia in patients with Prader-Willi syndrome (PWS). Soleno reported 1,043 patient start forms received since the drug's approval in March 2025, with 764 active patients on the drug as of September 30.

Despite these seemingly positive results, the sharp decline in Soleno's stock price suggests that investors may have had even higher expectations or are concerned about other factors not immediately apparent in the headline numbers. Possible reasons for the sell-off could include: 1. Valuation concerns: The stock may have been priced for perfection, and even strong results couldn't justify its current valuation. 2. Future growth worries: Investors might be questioning the long-term growth potential of VYKAT XR or the company's pipeline. 3. Competitive landscape: There could be concerns about potential competition in the PWS treatment market. 4. Profit-taking: Some investors may be selling to lock in gains, as biotech stocks can be volatile following earnings releases. As the market digests the full earnings report and management's commentary during the conference call, it will be crucial to watch for any additional insights that might explain the stock's dramatic after-hours movement.